Many studies have been conducted and proven by Ratziu et al. [4] and Aithal et al. [5] that enhancing insulin sensitivity through administering drugs in the classes of thiazolidinediones improves insulin sensitivity in patients with NASH. This evidence concerns the gene INS and metabolic dysfunction-associated steatohepatitis.